Annovis Bio Stock Alpha and Beta Analysis
| ANVS Stock | USD 3.01 0.05 1.63% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Annovis Bio. It also helps investors analyze the systematic and unsystematic risks associated with investing in Annovis Bio over a specified time horizon. Remember, high Annovis Bio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Annovis Bio's market risk premium analysis include:
Beta 1.03 | Alpha 0.73 | Risk 7.33 | Sharpe Ratio 0.11 | Expected Return 0.8 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Annovis Bio Backtesting, Annovis Bio Valuation, Annovis Bio Correlation, Annovis Bio Hype Analysis, Annovis Bio Volatility, Annovis Bio History and analyze Annovis Bio Performance. Annovis Bio Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Annovis Bio market risk premium is the additional return an investor will receive from holding Annovis Bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Annovis Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Annovis Bio's performance over market.| α | 0.73 | β | 1.03 |
Annovis Bio expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Annovis Bio's Buy-and-hold return. Our buy-and-hold chart shows how Annovis Bio performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Annovis Bio Market Price Analysis
Market price analysis indicators help investors to evaluate how Annovis Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Annovis Bio shares will generate the highest return on investment. By understating and applying Annovis Bio stock market price indicators, traders can identify Annovis Bio position entry and exit signals to maximize returns.
Annovis Bio Return and Market Media
The median price of Annovis Bio for the period between Sun, Oct 26, 2025 and Sat, Jan 24, 2026 is 3.46 with a coefficient of variation of 27.99. The daily time series for the period is distributed with a sample standard deviation of 0.92, arithmetic mean of 3.28, and mean deviation of 0.78. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Is a relief rally coming for Annovis Bio Inc. holders - Market Movers Growth Focused Stock Pick Reports - newser.com | 11/11/2025 |
2 | Acquisition by Michael Hoffman of 15000 shares of Annovis Bio at 2.11 subject to Rule 16b-3 | 11/14/2025 |
3 | Annovis Bio Director Michael Hoffman Acquires 15,000 Shares of Stock | 11/19/2025 |
4 | Acquisition by Michael Hoffman of 10000 shares of Annovis Bio at 3.49 subject to Rule 16b-3 | 11/21/2025 |
5 | Annovis Announces Two Presentations at the CTAD 2025 Conference | 11/24/2025 |
6 | Annovis Bio, Inc. Receives Consensus Rating of Hold from Brokerages - MarketBeat | 12/01/2025 |
7 | Why Annovis Bio Inc. stock is a must watch ticker - Earnings Risk Report Weekly Watchlist for Consistent Profits - Newser | 12/05/2025 |
8 | Acquisition by Michael Hoffman of 30000 shares of Annovis Bio at 4.3398 subject to Rule 16b-3 | 12/08/2025 |
9 | Amyotrophic Lateral Sclerosis Market Outlook Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period DelveInsight | 12/09/2025 |
10 | Annovis Announces Open-Label Extension Study for Parkinsons Disease Patients | 12/18/2025 |
11 | Annovis Bio stock hits 52-week low at 4.05 amid market challenges - MSN | 01/05/2026 |
12 | Annovis Bio, Inc. Receives Average Recommendation of Hold from Analysts - MarketBeat | 01/21/2026 |
About Annovis Bio Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Annovis or other stocks. Alpha measures the amount that position in Annovis Bio has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Annovis Bio Upcoming Company Events
As portrayed in its financial statements, the presentation of Annovis Bio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Annovis Bio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Annovis Bio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Annovis Bio. Please utilize our Beneish M Score to check the likelihood of Annovis Bio's management manipulating its earnings.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Annovis Bio
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.